Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 12, Pages 4414
Publisher
MDPI AG
Online
2020-06-23
DOI
10.3390/ijms21124414
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
- (2020) M. Chalabi et al. ANNALS OF ONCOLOGY
- Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
- (2020) Mark P. Chao et al. Frontiers in Oncology
- A new perspective in cancer immunotherapy: PD-1 on myeloid cells takes center stage in orchestrating immune checkpoint blockade
- (2020) Christopher E. Rudd Science Immunology
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sex-associated molecular differences for cancer immunotherapy
- (2020) Youqiong Ye et al. Nature Communications
- Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers
- (2019) Christopher J. D. Wallis et al. JAMA Oncology
- Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer
- (2019) Edith Borcoman et al. OncoImmunology
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
- (2019) Martin Reck et al. Lancet Respiratory Medicine
- Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
- (2019) Kyung Hae Jung et al. CLINICAL CANCER RESEARCH
- Impact of cholesterolemia and body mass index on outcome of metastatic non small cell lung cancer treated with immunotherapy.
- (2019) Giulia Galli et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of immune checkpoint therapy for cancer
- (2019) Jill M. Fritz et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Re-education of macrophages as a therapeutic strategy in cancer
- (2019) Joanna Kowal et al. Immunotherapy
- Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer
- (2019) Chengdi Wang et al. Cancer Medicine
- Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
- (2019) Selena Vigano et al. Frontiers in Immunology
- Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment
- (2019) Juliane Günther et al. Frontiers in Immunology
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
- (2019) Shixiang Wang et al. MOLECULES
- The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients
- (2019) Douglas Donnelly et al. Journal for ImmunoTherapy of Cancer
- Gender medicine and oncology: report and consensus of an ESMO workshop
- (2019) A D Wagner et al. ANNALS OF ONCOLOGY
- LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
- (2019) A-L Cheng et al. ANNALS OF ONCOLOGY
- Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
- (2019) Diego Chowell et al. NATURE MEDICINE
- Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers
- (2019) Gabriele Galliverti et al. Cancer Immunology Research
- ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer
- (2019) Guru Sonpavde et al. Future Oncology
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
- (2018) L Derosa et al. ANNALS OF ONCOLOGY
- Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm
- (2018) Steven M. Bair et al. Clinical Lymphoma Myeloma & Leukemia
- Adenosine receptors differentially regulate type 2 cytokine production by IL-33–activated bone marrow cells, ILC2s, and macrophages
- (2018) Balázs Csóka et al. FASEB JOURNAL
- Adenosine signaling and the immune system: When a lot could be too much
- (2018) Luca Antonioli et al. IMMUNOLOGY LETTERS
- Do immune checkpoint inhibitors perform identically in patients with weight extremes?
- (2018) Elie El Rassy et al. Immunotherapy
- Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)
- (2018) Yingcheng Wu et al. INTERNATIONAL JOURNAL OF CANCER
- Patient-Reported Functional Status in Outpatients With Advanced Cancer: Correlation With Physician-Reported Scores and Survival
- (2018) Gordana Popovic et al. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
- Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma
- (2018) Arlene O. Siefker-Radtke et al. JOURNAL OF UROLOGY
- Does a patient's sex predict the efficacy of cancer immunotherapy?
- (2018) Omar Abdel-Rahman LANCET ONCOLOGY
- Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
- (2018) Fabio Conforti et al. LANCET ONCOLOGY
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
- (2018) Jake S. O’Donnell et al. SEMINARS IN CANCER BIOLOGY
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Immunological monitoring for prediction of clinical response to antitumor vaccine therapy
- (2018) Irina N. Mikhaylova et al. Oncotarget
- Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer
- (2018) Taku Fujimura et al. Frontiers in Oncology
- Combinations of Bevacizumab With Cancer Immunotherapy
- (2018) Daniel S. Chen et al. CANCER JOURNAL
- Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
- (2018) Tara C. Mitchell et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the IDO1 pathway in cancer: from bench to bedside
- (2018) Ming Liu et al. Journal of Hematology & Oncology
- 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer
- (2018) Hossein Borghaei et al. Journal of Thoracic Oncology
- Sex as a predictor of response to cancer immunotherapy
- (2018) Hyunwoo Kwon et al. LANCET ONCOLOGY
- Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
- (2018) Alexander J. Muller et al. Seminars in Immunopathology
- Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors
- (2018) Jibran Ahmed et al. OncoImmunology
- Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
- (2018) Yinghong Wang et al. NATURE MEDICINE
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
- (2018) Ranjana Advani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
- (2018) Antonino Grassadonia et al. Journal of Clinical Medicine
- Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
- (2018) Takefumi Komiya et al. Frontiers in Oncology
- The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
- (2017) Lieve Brochez et al. EUROPEAN JOURNAL OF CANCER
- A drug development perspective on targeting tumor-associated myeloid cells
- (2017) Meher Majety et al. FEBS Journal
- Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC).
- (2017) Howard S. Hochster et al. JOURNAL OF CLINICAL ONCOLOGY
- De-novo and acquired resistance to immune checkpoint targeting
- (2017) Nicholas L Syn et al. LANCET ONCOLOGY
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
- (2017) Andrea Botticelli et al. Oncotarget
- Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients
- (2017) Arthur E. Frankel et al. NEOPLASIA
- Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy
- (2017) Andrea Facciabene et al. OncoImmunology
- Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
- (2017) Michael A. Cannarile et al. Journal for ImmunoTherapy of Cancer
- Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
- (2016) Arabella Young et al. CANCER CELL
- Microbiome and Anticancer Immunosurveillance
- (2016) Laurence Zitvogel et al. CELL
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- PI3Kγ is a molecular switch that controls immune suppression
- (2016) Megan M. Kaneda et al. NATURE
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Obesity Paradox in Cancer: a Review
- (2016) Hannah Lennon et al. Current Oncology Reports
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
- (2016) Caroline Jochems et al. Oncotarget
- Overweight and obesity predict better overall survival rates in cancer patients with distant metastases
- (2016) Ngan Ming Tsang et al. Cancer Medicine
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
- (2015) Ping-Chih Ho et al. CELL
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- Proton pump inhibitors alter the composition of the gut microbiota
- (2015) Matthew A Jackson et al. GUT
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Multi-Inhibitory Effects of A2AAdenosine Receptor Signaling on Neutrophil Adhesion Under Flow
- (2015) Tadayuki Yago et al. JOURNAL OF IMMUNOLOGY
- Differential impact of obesity and diabetes mellitus on survival after liver resection for colorectal cancer metastases
- (2015) Sousana Amptoulach et al. JOURNAL OF SURGICAL RESEARCH
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- T cell exclusion, immune privilege, and the tumor microenvironment
- (2015) J. A. Joyce et al. SCIENCE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Immunological mechanisms of the antitumor effects of supplemental oxygenation
- (2015) Stephen M. Hatfield et al. Science Translational Medicine
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Obesity paradox in cancer: new insights provided by body composition
- (2014) Maria Cristina Gonzalez et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
- (2014) I. Chevolet et al. BRITISH JOURNAL OF DERMATOLOGY
- Association of obesity and overweight with overall survival in colorectal cancer patients: a meta-analysis of 29 studies
- (2014) Shuangjie Wu et al. CANCER CAUSES & CONTROL
- Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: a prospective study and meta-analysis
- (2014) Sabrina Schlesinger et al. CANCER CAUSES & CONTROL
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
- (2014) Carola H. Ries et al. CANCER CELL
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
- (2014) Khaled Ali et al. NATURE
- Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
- (2014) A. Young et al. Cancer Discovery
- Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway
- (2014) R. Abu-Eid et al. Cancer Immunology Research
- Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
- (2014) I. Theate et al. Cancer Immunology Research
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia
- (2013) Andrew M. Brunner et al. AMERICAN JOURNAL OF HEMATOLOGY
- Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
- (2013) Klaus Okkenhaug Annual Review of Immunology
- Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
- (2013) B. Allard et al. CLINICAL CANCER RESEARCH
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- An Epidemiologic and Genomic Investigation Into the Obesity Paradox in Renal Cell Carcinoma
- (2013) A. Ari Hakimi et al. JNCI-Journal of the National Cancer Institute
- Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch
- (2013) Patrick M Gubser et al. NATURE IMMUNOLOGY
- PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
- (2013) Minmin Song et al. PLoS One
- Role of PI3K/Akt signaling in memory CD8 T cell differentiation
- (2013) Eui Ho Kim et al. Frontiers in Immunology
- Interactions Between the Microbiota and the Immune System
- (2012) L. V. Hooper et al. SCIENCE
- Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity
- (2011) Sebastian F. M. Häusler et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy
- (2011) Marc Baay et al. Clinical & Developmental Immunology
- Upregulated Expression of Indoleamine 2, 3-Dioxygenase in Primary Breast Cancer Correlates with Increase of Infiltrated Regulatory T CellsIn Situand Lymph Node Metastasis
- (2011) Jinpu Yu et al. Clinical & Developmental Immunology
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
- (2011) Andrea Facciabene et al. NATURE
- International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors--An Update
- (2011) B. B. Fredholm et al. PHARMACOLOGICAL REVIEWS
- Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myelogenous Leukemia (AML) in Adults
- (2010) Willis H. Navarro et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Nathanael L. Dirks et al. CLINICAL PHARMACOKINETICS
- The emerging mechanisms of isoform-specific PI3K signalling
- (2010) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism
- (2010) N. T. Nguyen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Arginase: an emerging key player in the mammalian immune system
- (2009) Markus Munder BRITISH JOURNAL OF PHARMACOLOGY
- Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling
- (2009) Carsten Linnemann et al. IMMUNOLOGY
- Anergic T Cells Are Metabolically Anergic
- (2009) Y. Zheng et al. JOURNAL OF IMMUNOLOGY
- HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma
- (2008) L. Y. Han et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started